Skip to main content
    C

    CytomX Therapeutics Inc (CTMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.99
    -0.06 (-2.70%)

    Market Cap: $444.73M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CytomX Therapeutics Inc (CTMX) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    CytomX Therapeutics (CTMX) trades at 31.0x sales and 1.5x book value. Its P/S of 31.0x is above its 5-year median of 1.8x. Its forward P/E is 14.2x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E14.2x
    Price to sales31.0x
    Price to book1.5x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 400.0% above 6.2x.

    MultipleCurrent5-year median10-year median
    P/S31.0x1.8x6.2x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 0.6x in 2024 to 26.5x in 2016.

    Year endPriceP/EP/SP/B
    2025$4.26N/A5.5x7.3x
    2024$1.032.6x0.6xN/A
    2023$1.55N/A1.1xN/A
    2022$1.60N/A2.0xN/A
    2021$4.33N/A7.3xN/A
    2020$6.55N/A4.4xN/A
    2019$8.31N/A13.8x7.4x
    2018$15.10N/A10.4x5.2x
    2017$21.11N/A11.0x11.7x
    2016$10.99N/A26.5x5.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About CTMX

    What is CTMX's forward P/E ratio?

    CytomX Therapeutics has a forward P/E ratio of 14.2x.

    What is CTMX's price to sales ratio?

    CytomX Therapeutics has a price to sales ratio of 31.0x.